Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

A shorter radiotherapy (RT) course proved its mettle in early-stage breast cancer in terms of lymphedema risk, without ...

Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – showed that nearly two-thirds (61.6%) of patients with brain metastases ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company ...

Press conference: 12:30-13:15 CEST - ESMO Press Conference room, CC3 and virtually Presidential Symposium III, Eyes to the future: 16:30-18:15 CEST - Barcelona Auditorium - Hall 2 Organ agnostic ...